The most recent issue of the The International Journal of Transpersonal Studies is dedicated to studies and discussions examining the promises and risks associated with the recent upsurge of interest within mainstream psychiatry in the drug ketamine for the treatment of depression.
The introductory editorial discusses the different effects of ketamine at different dosages and asks whether the positive effects in depression studies are actually emerging from ketamine’s psychedelic properties. If so, the editorial asks, what might that mean for attempts by conventional psychiatrists — who tend to be biased against psychedelics — to find a working low-dose, long-term-use application for the drug?
All of the studies and commentaries are publicly accessible.
Meanwhile, the Office of Women’s Health of the US Department of Health and Human Services reminds the public that at certain doses ketamine has also been used as a “drug-facilitated sexual assault” tool, or “date-rape” drug.
Date rape drugs fact sheet (Womenshealth.gov, accessed June 29, 2015)